Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations.
We reviewed information about the safety and plasma pharmacokinetic data for amoxicillin, specifically related to its potential use for postexposure inhalational anthrax. Amoxicillin (45 mg/kg/d) given orally in 3 divided doses to pediatric patients <40 kg should yield an adequate time above the MIC for susceptible Bacillus anthracis (< or =0.5 microg/mL) over most of the dosing interval (75-100%). Doses <45 mg/kg/d and dosing intervals longer than 8 hours should not be used for postexposure inhalational anthrax.
Alexander
John J
JJ
Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Colangelo
Philip M
PM
Cooper
Charles K
CK
Roberts
Rosemary
R
Rodriguez
William J
WJ
Murphy
Mary D
MD
D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000881:Anthrax / Q000188:drug therapy / Q000517:prevention & control*; D001408:Bacillus anthracis / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019570:Inhalation Exposure; D008826:Microbial Sensitivity Tests
D000658:Amoxicillin